Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 4
2005 3
2006 2
2007 2
2008 4
2009 4
2010 4
2011 5
2012 1
2013 3
2014 8
2015 7
2016 3
2017 5
2018 8
2019 2
2020 1
2021 3
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Results by year
Filters applied: . Clear all
Page 1
Primary Hyperparathyroidism.
Insogna KL. Insogna KL. N Engl J Med. 2018 Sep 13;379(11):1050-1059. doi: 10.1056/NEJMcp1714213. N Engl J Med. 2018. PMID: 30207907 Review. No abstract available.
A clinician's guide to X-linked hypophosphatemia.
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. Carpenter TO, et al. Among authors: insogna kl. J Bone Miner Res. 2011 Jul;26(7):1381-8. doi: 10.1002/jbmr.340. Epub 2011 May 2. J Bone Miner Res. 2011. PMID: 21538511 Free PMC article. Review.
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism.
Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Minisola S, et al. Among authors: insogna kl. J Bone Miner Res. 2022 Nov;37(11):2315-2329. doi: 10.1002/jbmr.4665. Epub 2022 Oct 17. J Bone Miner Res. 2022. PMID: 36245271 Review.
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.
Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, Kleinstein SH, Abel ED, Insogna KL, Feske S, Locasale JW, Bosenberg MW, Rathmell JC, Kaech SM. Ho PC, et al. Among authors: insogna kl. Cell. 2015 Sep 10;162(6):1217-28. doi: 10.1016/j.cell.2015.08.012. Epub 2015 Aug 27. Cell. 2015. PMID: 26321681 Free PMC article.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO; AXLES 1 Investigators. Insogna KL, et al. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. J Bone Miner Res. 2018. PMID: 29947083 Free article. Clinical Trial.
Primary Hyperparathyroidism.
Insogna KL. Insogna KL. N Engl J Med. 2018 Dec 20;379(25):e43. doi: 10.1056/NEJMc1813648. N Engl J Med. 2018. PMID: 30575486 No abstract available.
New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D, Insogna KL. Athonvarangkul D, et al. Among authors: insogna kl. Calcif Tissue Int. 2021 Jan;108(1):143-157. doi: 10.1007/s00223-020-00705-3. Epub 2020 Jun 5. Calcif Tissue Int. 2021. PMID: 32504139 Review.
69 results